Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

被引:9
作者
Chetwood, John David [1 ,2 ,10 ]
Tran, Yvonne [3 ]
Subramanian, Sreedhar [4 ]
Smith, Philip J. [5 ]
Iborra, Marisa [6 ]
Buisson, Anthony [7 ,8 ]
Paramsothy, Sudarshan [1 ,2 ,9 ]
Leong, Rupert W. [1 ,2 ,9 ]
机构
[1] Concord Repatriat Gen Hosp, Dept Gastroenterol & Hepatol, Sydney, NSW, Australia
[2] Univ Sydney, Concord Clin Sch, Sydney, NSW, Australia
[3] Macquarie Univ, Australian Inst Hlth Innovat, Ctr Healthcare Resilience & Implementat Sci, Sydney, NSW, Australia
[4] Cambridge Univ Hosp Fdn Trust, Dept Gastroenterol, Cambridge, England
[5] Liverpool Univ Hosp NHS Fdn Trust, Royal Liverpool Hosp, Dept Gastroenterol, Liverpool, England
[6] La Fe Univ Hosp Valencia, Dept Gastroenterol, Valencia, Spain
[7] Univ Clermont Auvergne, Ctr Hosp Univ Clermont Ferrand, Serv Hepatogastro Enterol, INSERM,3iHP, Clermont Ferrand, France
[8] Univ Clermont Auvergne, USC INRA 2018, INSERM U1071, M2iSH,3iHP, Clermont Ferrand, France
[9] Macquarie Univ, Fac Med & Hlth Sci, Sydney, NSW, Australia
[10] Level 1 West, Hosp Rd, Concord 2137, Australia
关键词
Infliximab; Subcutaneous; CT-P13; Inflammatory bowel disease; REAL-WORLD; MAINTENANCE; EXPERIENCE; EFFICACY; THERAPY; SAFETY; SWITCH;
D O I
10.1093/ecco-jcc/jjae059
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Subcutaneous [SC] infliximab may provide multiple benefits over intravenous [IV] formulations. However, studies for efficacy and safety in inflammatory bowel disease [IBD] have been constrained by small sizes that limit the interpretation of outcomes, particularly for subgroups potentially at high risk of disease relapse.Methods We conducted a systematic review and random-effects meta-analysis up to January 2023, to evaluate the change in clinical remission after transitioning from IV to SC infliximab in patients with IBD in clinical remission. The primary outcome was measured using the relative risk for meta-analysis.Results We identified 15 studies of patients established >= 3 months on IV infliximab, consisting of 1371 patients and 840 patient-years of follow-up. There was no loss of clinical remission in the IBD cohort overall, Crohn's disease [CD], or perianal CD [p = 0.55 and p = 0.11 at 9-12 months, and p = 0.50 at 6 months, respectively]. Neither prior IV dose [<= 10 mg/kg 6-weekly] [p = 0.48] nor IBD disease subtype was associated with an increased clinical relapse rate at 6 months (p = 0.48 and p = 0.45 [UC vs CD], respectively).Conclusion Changing patients established on IV infliximab to an SC formulation is associated with a high ongoing clinical remission and a low adverse event rate. Furthermore, there are no signals for adverse outcomes among different IBD disease subtypes, nor in those on escalated IV infliximab dosing schedules up to 10 mg/kg 6-weekly. These data should provide patients and clinicians alike with confidence in SC infliximab use in IBD.
引用
收藏
页码:1440 / 1449
页数:10
相关论文
共 32 条
[1]  
[Anonymous], 2021, AUSTR NZ CLIN TRIALS
[2]   Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results [J].
Arguelles-Arias, Federico ;
Fernandez Alvarez, Paula ;
Castro Laria, Luisa ;
Maldonado Perez, Belen ;
Belvis Jimenez, Maria ;
Merino-Bohorquez, Vicente ;
Caunedo Alvarez, Angel ;
Calleja Hernandez, Miguel Angel .
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2022, 114 (02) :118-119
[3]   Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study [J].
Buisson, Anthony ;
Nachury, Maria ;
Reymond, Maud ;
Yzet, Clara ;
Wils, Pauline ;
Payen, Laure ;
Laugie, Marie ;
Manlay, Luc ;
Mathieu, Nicolas ;
Pereira, Bruno ;
Fumery, Mathurin .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (09) :2338-2346
[4]   Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis [J].
Caporali, Roberto ;
Allanore, Yannick ;
Alten, Rieke ;
Combe, Bernard ;
Durez, Patrick ;
Iannone, Florenzo ;
Nurmohamed, Mike T. ;
Lee, Sang Joon ;
Kwon, Taek Sang ;
Choi, Jean Soo ;
Park, Gahee ;
Yoo, Dae Hyun .
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2021, 17 (01) :85-99
[5]  
Colombel JF, 2023, J CROHNS COLITIS, V17, pI161
[6]  
Colomino MII, 2023, J CROHNS COLITIS, V17, P517
[7]   Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials [J].
Combe, Bernard ;
Allanore, Yannick ;
Alten, Rieke ;
Caporali, Roberto ;
Durez, Patrick ;
Iannone, Florenzo ;
Nurmohamed, Michael T. ;
Toumi, Mondher ;
Lee, Sang Joon ;
Kwon, Taek Sang ;
Noh, Jiwon ;
Park, Gahee ;
Yoo, Dae Hyun .
ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
[8]  
Cornelis L., 2022, UNITED EUROPEAN GAST, V10, P712
[9]  
Cribari-Neto F, 2010, J STAT SOFTW, V34, P1
[10]   An updated systematic review and meta-analysis about the safety and efficacy of infliximab biosimilar, CT-P13, for patients with inflammatory bowel disease [J].
Ebada, Mahmoud Ahmed ;
Elmatboly, Abdelmagid M. ;
Ali, Ahmed Said ;
Ibrahim, Ahmed Mohamed ;
Fayed, Notila ;
Faisal, Ahmed Faisal ;
Alkanj, Souad .
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2019, 34 (10) :1633-1652